IQVIA Holdings Inc

IQVIA Holdings Inc(IQV)股票分析

$266.900

-4.084 (-1.53%)收盘时

Loading chart…
最高
272.980
开盘
271.920
成交量加权均价
267.70
成交量
1.04M
市值
38.76B
最低
263.210
成交额
277.62M
企业价值/息税折旧摊销前利润(TTM)
16.35

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others.

AI 分析 of IQVIA Holdings Inc (IQV)

买入

IQVIA Holdings Inc is a good buy right now due to its strong financial performance and positive market sentiment. The current price of $266.90 is below the average analyst price target of $305, suggesting a potential upside of approximately 14%. Additionally, the forward P/E ratio is 18.42, which is attractive compared to the current P/E of 32.18, indicating that the stock may be undervalued relative to its future earnings potential. However, the main risk is the insider selling, with executives reducing their holdings by 19%, which may signal caution regarding future performance.

分析师评级(17)

-3.22% 下跌空间
买入
9 买入
8 持有
0 卖出
当前: 266.90
最低
215.00
平均
258.31
最高
290.00

BofA

2026-10-09

目标价

$305

买入

Mizuho

2026-10-07

目标价

$300

跑赢大盘

Barclays

2026-10-07

目标价

$300

增持

UBS

2026-09-30

目标价

$345

买入

RBC Capital

2026-09-29

目标价

$319

跑赢大盘

估值指标

IQVIA Holdings Inc(IQV)当前预期市盈率为 18.42,5 年平均预期市盈率为 18.98。

预期市盈率

合理
5 年均值 P/E
18.98
当前P/E
18.42
高估
22.30
低估
15.65

预期 EV/EBITDA

高估
5 年均值 EV/EBITDA
13.79
当前EV/EBITDA
16.35
高估
15.91
低估
11.66

预期市销率

合理
5 年均值 P/S
2.42
当前P/S
2.40
高估
2.90
低估
1.95

Alphio AI 对 IQV 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%IQV

$150.52

情景价格

基

基准

基准 · 50%IQV

$139.87

情景价格

悲

悲观

悲观 · 25%IQV

$124.38

情景价格

持有 IQV 的大户

S

Singapore

+ 持有IQVTSM

+14.33%

3个月收益率

H

Howard Capital Management, Inc.

+ 持有IQV

+12.71%

3个月收益率

C

Campbell & Company, LP

+ 持有IQV

+9.49%

3个月收益率

E

Edmond de Rothschild Asset Management (France)

+ 持有IQV

+7.54%

3个月收益率

L

Lakewood Capital Management, LP

+ 持有IQV

+6.37%

3个月收益率

T

Trajan Wealth, L.L.C.

+ 持有IQV

+5.22%

3个月收益率

事件时间线

2026-10-13 (ET)

07:30:00

IQVIA and Veeva Expand Partnership

2026-10-07 (ET)

16:30:00

Iqvia Launches Iqvia Explorer to Enhance Commercial Decision-Making

16:30:00

Iqvia Launches Life Science Models to Predict Clinical Trial Outcomes

2026-09-15 (ET)

09:30:00

The Trade Desk Expands Integrations with Veeva and IQVIA

2026-09-09 (ET)

08:30:00

IQVIA Plans to Raise $2 Billion Through Senior Notes Offering

资讯

IQV 常见问题 —— 由 Alphio AI 解答

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

IQVIA Holdings Inc is a good buy right now due to its strong financial performance and positive market sentiment. The current price of $266.90 is below the average analyst price target of $305, suggesting a potential upside of approximately 14%. Additionally, the forward P/E ratio is 18.42, which is attractive compared to the current P/E of 32.18, indicating that the stock may be undervalued relative to its future earnings potential. However, the main risk is the insider selling, with executives reducing their holdings by 19%, which may signal caution regarding future performance.

17 analysts cover IQV: 9 rate it Buy, 8 Hold and 0 Sell. The average price target is 258.31.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易